• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Kancera

Less than 1K followers
Overview
Ownership
Investor consensus
All
Webcasts
Press releases
ShowingAll content types

Press release3/31/2026, 6:00 AM

Novakand Pharma to hold Extraordinary General Meeting to decide on future business direction – Comments from the board of directors

Kancera
Press release3/2/2026, 6:00 AM

Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting

Kancera
Press release2/25/2026, 3:45 PM

The board evaluates Novakand Pharma’s options after the decision not to execute the planned reverse take over of SVF Vaccines

Kancera

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2/12/2026, 4:45 PM

Novakand Pharma applies for Nasdaq’s approval of continued listing of the combined company post a completed reverse takeover with SVF Vaccines

Kancera
Press release2/6/2026, 7:00 AM

Novakand Pharma enters into share purchase agreement with SVF Vaccines regarding a reverse takeover

Kancera
Regulatory press release12/22/2025, 7:00 AM

Novakand Pharma enters Letter of Intent with SVF Vaccines regarding a reverse takeover

Kancera
Regulatory press release11/21/2025, 7:00 AM

Interim Report Third Quarter 2025, July 1 – September 30 Novakand Pharma AB (publ.), org.no. 556806-8851

Kancera
Press release10/9/2025, 7:00 AM

Novakand Pharma provides an update on the ongoing reverse take over process

Kancera
Regulatory press release9/23/2025, 1:00 PM

Peter Selin resigns as CEO of Novakand Pharma in mutual agreement with the board

Kancera
Regulatory press release9/22/2025, 2:00 PM

Kancera AB changes name to Novakand Pharma AB

Kancera
Regulatory press release9/18/2025, 4:00 PM

Kancera initiates process to seek stakeholders for a reverse take over

Kancera
Regulatory press release8/28/2025, 6:00 AM

Interim Report First Quarter 2025, April 1 – June 30 Kancera AB (publ.), org.no. 556806-8851

Kancera
Regulatory press release8/12/2025, 6:00 AM

Kancera terminates letter of intent with Recardio

Kancera
Press release6/16/2025, 6:30 AM

Kancera announces rugocrixan and fosrugocrixan as the International Non-proprietary Names for KAND567 and KAN145

Kancera
Regulatory press release6/13/2025, 6:00 AM

Kancera reports positive top-line results from the KANDOVA study

Kancera
Regulatory press release6/5/2025, 6:00 AM

Kancera reports positive outcome of pre-IND meeting with FDA

Kancera
Press release5/27/2025, 6:39 AM

Redeye: Kancera Q1 - Continued efforts with Recardio

Kancera
Regulatory press release5/23/2025, 6:00 AM

Interim Report First Quarter 2025, January 1 – March 31 Kancera AB (publ.), org.no. 556806-8851

Kancera
Press release5/20/2025, 6:30 AM

Kancera provides an update on the collaboration with Recardio Inc. and the company’s clinical development program

Kancera
Press release4/8/2025, 6:00 AM

Kancera reports Last Patient Last Visit in the KANDOVA study

Kancera